The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling

Most patients with multiple myeloma treated with current therapies, including immunomodulatory drugs, eventually develop relapsed/refractory disease. Clinical activity of lenalidomide relies on degradation of Ikaros and the consequent reduction in IRF4 expression, both required for myeloma cell surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Díaz, Tania, Rodríguez, Vanina, Lozano, Ester, Mena, Mari-Pau, Calderón, Marcos, Rosiñol, Laura, Martínez, Antonio, Tovar, Natalia, Pérez-Galán, Patricia, Bladé, Joan, Roué, Gaël, de Larrea, Carlos Fernández
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622862/
https://www.ncbi.nlm.nih.gov/pubmed/28751557
http://dx.doi.org/10.3324/haematol.2017.164632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622862/
https://www.ncbi.nlm.nih.gov/pubmed/28751557
http://dx.doi.org/10.3324/haematol.2017.164632

Ejemplares similares